Skip to main content
. 2018 Jul 6;9(9):1190–1193. doi: 10.1111/1759-7714.12799

Figure 1.

Figure 1

The serum tumor marker levels were stable after three cycles of nivolumab. After chemotherapy is administered, the serum tumor marker level continues to reduce.